Navigation Links
Copan Announces the Appointment of Bob Cooper as Vice President of Business Development in the Pacific Rim

LIMMERICK, Ireland, Feb. 16 /PRNewswire/ -- Copan Innovation Ltd., whose subsidiary Copan Italia, S.p.A. is the leading manufacturer of collection and transport systems in the world, has named Bob Cooper as its new Vice President of Business Development in the Pacific Rim, as well as appointed Mr. Cooper to the board of directors at Copan Innovation Ltd.

Bob Cooper, who brings a background of twenty five years in senior management positions at several international corporations in healthcare related industries, specifically nine years of experience in high technology laboratory automation, will be responsible for developing and managing a distribution network in the Pacific Rim for Copan's newly launched instrumentation for clinical microbiology. Copan has recently launched a complete line of products under the Copan Automation brand, and Mr. Cooper will lead the expansion in Asia, Australia and New Zealand. His experience in healthcare includes capital equipment, medical devices and software, intellectual property, licensing of technology, development of strategic alliances and international business, and his experience will facilitate Copan's expansion in the rapidly growing economies in the Pacific Rim.

"Bob's diversity of experience in the laboratory automation market and his wealth of direct international business experience will be essential to Copan's rapid market penetration in the clinical microbiology automation market," said Daniele Triva, Copan Innovation Ltd., CEO. "The launch of the new line of Liquid-Based Microbiology products and the WASP [Walk-Away Specimen Processor] are exciting projects for Copan and it solidifies our commitment to innovation in pre-analytics in clinical microbiology," added Mr. Triva.

Bob Cooper is the latest addition to Copan's growing team of professionals committed to the success of Copan's new venture, which in recent months have included the appointment of seasoned Business Development Managers in the US and Europe. Cooper's addition to the Copan leadership team, and the breakthrough technology behind the WASP, provide the ideal composition and opportunity for Copan to help laboratories in different parts of the world achieve efficiencies and productivity in microbiology specimen processing, where full automation had not previously existed.

About the Copan Group

With a reputation for innovation in preanalytics, the Copan Group, comprising of Copan Innovation Ltd., Copan Italia, S.p.A., Copan Diagnostics Inc. and MicroRheologics S.r.l., is the leading manufacturer and provider of collection and transport systems in the world. Copan offers a complete range of microbial sampling products used for traditional culture analysis and for molecular diagnostic assays, as well as producing innovations, like the patented Flocked Swabs, Universal Transport Medium and ESwab. The company manufactures a comprehensive line of laboratory consumables comprising of inoculation loops, needles, spreaders and transfer pipettes. Copan has recently launched WASP: Walk-Away Specimen Processor, a new revolutionary system for automatic planting and streaking of microbiology samples. For more information about Copan, visit

SOURCE Copan Innovation Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
2. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
5. Savient Announces Appointment of David Gionco as Chief Financial Officer
6. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
8. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
9. Cord Blood Announces $1 Million Reduction in Long Term Debt
10. BioMed Realty Trust Announces New Financing for Joint Venture With Prudential Real Estate Investors
11. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
Post Your Comments:
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
(Date:11/25/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; TSX: ... prospects remain fundamentally strong and highlights the following ... received DSMB recommendation to continue the ZoptEC Phase ... the final interim efficacy and safety data ... men with heavily pretreated castration- and Taxane-resistant prostate ...
Breaking Biology Technology:
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)...  Synaptics (NASDAQ: SYNA ), a leading developer of human ... September 30, 2015. --> --> ... 66 percent over the comparable quarter last year to $470.0 million. ... million, or $0.62 per diluted share. --> ... of fiscal 2016 grew 39 percent over the prior year period ...
Breaking Biology News(10 mins):